Results 21 to 30 of about 699,979 (258)

Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials

open access: yesOphthalmology and Therapy
Introduction Thyroid eye disease (TED) is a rare, autoimmune, orbital inflammatory disorder that is disfiguring, debilitating, and potentially sight-threatening.
Daniel Ezra   +7 more
doaj   +1 more source

Enteropathogenic E. coli shows delayed attachment and host response in human jejunum organoid‐derived monolayers compared to HeLa cells

open access: yesFEBS Letters, EarlyView.
Enteropathogenic E. coli (EPEC) infects the human intestinal epithelium, resulting in severe illness and diarrhoea. In this study, we compared the infection of cancer‐derived cell lines with human organoid‐derived models of the small intestine. We observed a delayed in attachment, inflammation and cell death on primary cells, indicating that host ...
Mastura Neyazi   +5 more
wiley   +1 more source

Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19

open access: yesТерапевтический архив, 2021
Aim. To determine the criteria for the optimal use of IL-6 receptor blockers in patients with COVID-19 community-acquired pneumonia based on predictors of adverse outcomes. Materials and methods.
Tatyana S. Kruglova   +11 more
doaj   +1 more source

Reciprocal control of viral infection and phosphoinositide dynamics

open access: yesFEBS Letters, EarlyView.
Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley   +1 more source

Giant Cell Arteritis Refractory to Interleukin‐6 and Interleukin‐17 Inhibition Treated With Upadacitinib

open access: yesACR Open Rheumatology
Giant cell arteritis (GCA) is a granulomatous vasculitis that can involve both cranial and extracranial vessels. Although interleukin‐6 (IL‐6) receptor blockade is an established therapy, treatment options for medically refractory disease remain limited.
Luke S. Vest   +4 more
doaj   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

open access: yesFEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta   +3 more
wiley   +1 more source

Expression of interleukin 1-alpha, interleukin 6 and CD 10 in predicting recurrence of ameloblastoma

open access: yesDiscover Oncology
Purpose Ameloblastoma (AM) is a clinically significant odontogenic tumour known for its local invasive and high post-treatment recurrence risk. Despite advancements in surgical techniques, predicting recurrence remains challenging.
Nurhazwani Mohd Danil   +3 more
doaj   +1 more source

Study on relationship between elderly sarcopenia and inflammatory cytokine IL-6, anti-inflammatory cytokine IL-10

open access: yesBMC Geriatrics, 2018
Background and objectives The pathophysiological mechanism of sarcopenia in the elderly has not yet been fully understood. Here, we aim to explore the relationship between sarcopenia and the inflammatory cytokine interleukin-6 (IL-6), and the anti ...
Yu-Dong Rong   +4 more
doaj   +1 more source

Recombinant production of human interleukin 6 in Escherichia coli. [PDF]

open access: yesPLoS ONE, 2013
In this study, we compared basic expression approaches for the efficient expression of bioactive recombinant human interleukin-6 (IL6), as an example for a difficult-to-express protein. We tested these approaches in a laboratory scale in order to pioneer
Henrik Nausch   +5 more
doaj   +1 more source

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

open access: yesFEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy